Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential 

– All tested doses of REL-1017, including the maximum tolerated dose, showed a highly statistically significant difference in abuse potential vs.
oxycodone with p-values <0.001

– Company to host conference call at 8:30 AM Eastern Time today July 27, 2021

See more here